Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease - Takeaways - MDSpire

Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease

  • By

  • Daisuke Ikeda

  • Ami Fukumoto

  • Yuka Uesugi

  • Rikako Tabata

  • Daisuke Miura

  • Kentaro Narita

  • Masami Takeuchi

  • Tomohisa Watari

  • Yoshihito Otsuka

  • Kosei Matsue

  • September 5, 2023

  • 0 min

Share

  • 1

    Prolonged viral shedding (PVS) in hematologic disease patients was observed in 36.9% of cases, with some patients not achieving viral clearance for over 42 days.

  • 2

    Patients with PVS exhibited significant depletion of CD4+ and CD19+ cells compared to those without PVS, indicating a link between immune deficits and prolonged infection.

  • 3

    The study found that recent treatment with anti-CD20 antibodies and bendamustine was associated with an increased risk of PVS in hematologic disease patients.

  • 4

    Patients with PVS demonstrated significantly lower neutralizing activity against Omicron subvariants compared to those without PVS, highlighting immune response challenges.

  • 5

    Among patients who died from COVID-19, all had a history of combination therapy with bendamustine and anti-CD20 antibodies, underscoring treatment risks.

Original Source(s)

Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease

  • by Daisuke Ikeda, Ami Fukumoto, Yuka Uesugi, Rikako Tabata, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Tomohisa Watari, Yoshihito Otsuka, Kosei Matsue

  • September 5, 2023

Related Content

Temple Lung Center | Enrolling Clinical Trials

The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.

  • by

  • March 23, 2026

  • 5 min
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19